Alexion Pharmaceuticals Inc.

ALXN NMS
Pharmaceuticals
New Haven, CT
2016 Revenue (US$ Millions)$3,084
Revenue Growth (%)18.43%
2015 Revenue (US$ Millions)$2,604
Net Income (US$ Millions)$399
Common Shares Outstanding (Millions)224
Earnings Per Share (US$)$1.76
Price to Earnings Ratio107.16
Total Equity (US$ Millions)$8,694
Return on Equity (%)4.83%
Long Term Debt (US$ Millions)$3,121
Debt to Equity Ratio (%)0.36%
Market Capitalization (US$ Millions)$27,406
Total Assets (US$ Millions)$13,253
Current Assets (US$ Millions)$2,578
Inventories (US$ Millions)$375
Current Liabilities (US$ Millions)$823
Cost Of Goods Sold (US$ Millions)$258
Asset Turnover0.23
Inventory Turnover0.78